Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $50.00, for a total value of $300,000.00. Following the sale, the chief executive officer now directly owns 824,106 shares of the company's stock, valued at approximately $41,205,300. The trade was a 0.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Tarsus Pharmaceuticals Price Performance
Shares of TARS stock traded up $1.09 on Friday, hitting $51.74. 499,104 shares of the company's stock were exchanged, compared to its average volume of 679,098. The company has a 50 day moving average of $49.00 and a 200 day moving average of $46.20. The stock has a market cap of $1.99 billion, a P/E ratio of -13.58 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. On average, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.
Institutional Trading of Tarsus Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of TARS. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $25,000. GF Fund Management CO. LTD. bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $44,000. R Squared Ltd bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $53,000. FMR LLC boosted its stake in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after purchasing an additional 3,537 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $166,000. Institutional investors own 90.01% of the company's stock.
Analyst Ratings Changes
A number of analysts have issued reports on TARS shares. Barclays cut their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. HC Wainwright restated a "buy" rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Jefferies Financial Group lifted their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Oppenheimer increased their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $63.67.
Read Our Latest Report on TARS
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Recommended Stories
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
